Painreform Ltd (PRFX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Painreform Ltd stock (PRFX) is currently trading at $2.20. Painreform Ltd PE ratio is 0.03. Analyst consensus price target for PRFX is $12.00. WallStSmart rates PRFX as Sell.
- PRFX PE ratio analysis and historical PE chart
- PRFX PS ratio (Price-to-Sales) history and trend
- PRFX intrinsic value — DCF, Graham Number, EPV models
- PRFX stock price prediction 2025 2026 2027 2028 2029 2030
- PRFX fair value vs current price
- PRFX insider transactions and insider buying
- Is PRFX undervalued or overvalued?
- Painreform Ltd financial analysis — revenue, earnings, cash flow
- PRFX Piotroski F-Score and Altman Z-Score
- PRFX analyst price target and Smart Rating
Painreform
📊 No data available
Try selecting a different time range
PRFX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Painreform Ltd (PRFX)
PRFX trades at a significant discount to its Graham intrinsic value of $203.32, offering a 98% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Painreform Ltd (PRFX) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Painreform Ltd (PRFX) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Painreform Ltd (PRFX) Areas to Watch (3)
Company is destroying shareholder value
Very low institutional interest at 2.45%
Micro-cap company with very limited liquidity and high volatility
Painreform Ltd (PRFX) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 1 register as strengths (avg 10.0/10) while 3 fall into concern territory (avg 1.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.21) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Institutional Own., Market Cap. Profitability pressure is visible in Return on Equity at -127.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -127.60% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Institutional Own. are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PRFX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PRFX's Price-to-Sales ratio of 74.91x trades 83% above its historical average of 41.04x (87th percentile), historically expensive. The current valuation is 53% below its historical high of 160.11x set in Jul 2023, and 1335% above its historical low of 5.22x in Aug 2024. Over the past 12 months, the PS ratio has expanded from ~50.8x, reflecting growing market expectations outpacing revenue growth.
Compare PRFX with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Painreform Ltd (PRFX) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Painreform Ltd operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Free cash flow is -991,000, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Painreform Ltd.
Bottom Line
Painreform Ltd offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:00:49 AM
About Painreform Ltd(PRFX)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
PainReform Ltd., a pharmaceutical company specializing in clinical stages, is dedicated to the development of therapies that provide an extended period of post-surgical pain relief in Israel. The company is headquartered in Tel Aviv, Israel.